Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Double-Blind, Placebo-Controlled, Phase 2 Trial to Test Efficacy and Safety of AV-101 (L-4-chlorokynurenine) as Adjunct to Current Antidepressant Therapy in Patients With Major Depressive Disorder (the ELEVATE Study)

Next Previous
Trial Profile

Double-Blind, Placebo-Controlled, Phase 2 Trial to Test Efficacy and Safety of AV-101 (L-4-chlorokynurenine) as Adjunct to Current Antidepressant Therapy in Patients With Major Depressive Disorder (the ELEVATE Study)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 21 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AV 101 (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Acronyms ELEVATE
  • Sponsors VistaGen Therapeutics

    • Most Recent Events

    • 14 Nov 2019 According to a VistaGen Therapeutics media release, the company will continue to examine the full dataset from this study to evaluate effects on other endpoints and pharmacokinetics.
    • 14 Nov 2019 Topline results presented in a VistaGen Therapeutics media release.
    • 08 Oct 2019 According to a VistaGen Therapeutics media release, the company announced that the last patient has completed the dosing. The company remains on track to report the top line results of this study before the end of 2019.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top